<DOC>
	<DOC>NCT00746837</DOC>
	<brief_summary>The purpose of the study is to estimate the absolute bioavailability at steady state of 2 doses of AZD5672 (50 mg and 150 mg administered orally once daily)</brief_summary>
	<brief_title>AZD5672 Absolute Bioavailability Study</brief_title>
	<detailed_description />
	<mesh_term>N-(1-(3-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-methanesulfonylphenyl)acetamide</mesh_term>
	<criteria>Provision of informed consent prior to any study specific procedures. Females should not be of childbearing potential Clinically normal physical and laboratory findings as judged by the investigator, including negative test results for drugofabuse, alcohol and cotinine at the Screening Visit and/or admission (Day 1) of each study period, and negative test results Any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subject's ability to participate Unsuitable venous access for intravenous studies Participation in a clinical study involving an investigational product within 5 halflives of active moieties of the last dose of investigational product or 3 months prior to first dosing (whichever is longer).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>AZD5672</keyword>
</DOC>